Sentinel lymph node localization in early breast cancer.
1998; National Institutes of Health; Volume: 39; Issue: 8 Linguagem: Inglês
Autores
Seza A. Güleç, Frederick L. Moffat, Robert G. Carroll, Aldo N. Serafini, George N. Sfakianakis, Lisa R. Allen, Jodeen E. Boggs, Dora Escobedo, Christopher S. Pruett, Anurag Gupta, Alan S. Livingstone, David N. Krag,
Tópico(s)Cutaneous Melanoma Detection and Management
ResumoThirty-two patients with clinical node-negative breast cancer underwent sentinel node localization study as part of a National Cancer Institute-sponsored multicenter trial. Anatomical and histopathologic characteristics of sentinel lymph node (SLN) and a kinetic analysis of nodal uptake were studied. Patients were injected with 1 mCi/4 ml unfiltered 99mTc-sulfur colloid in four divided doses around the palpable lesion or immediately adjacent to the excision cavity if prior biopsy was performed. SLN biopsy was performed 1.5-6 hr (mean = 3 hr) postinjection. Intraoperative localization was performed using a gamma probe. All patients underwent complete axillary dissection.SLN was identified in 30 of 32 (94%) patients. There were no false-negative SLN biopsies.This study supports the clinical validity of SLN biopsy in breast cancer and confirms that, unlike the blue dye technique, the learning curve with unfiltered 99mTc-sulfur colloid and the gamma detection probe is short, and SLN localization is achievable in over 90% of cases by surgeons with modest experience. The use of unfiltered 99mTc-sulfur colloid (larger particle size) with larger injected volume permits effective localization of SLNs.
Referência(s)